Teleflex Incorporated (TFX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: a positive shareholder return plan with significant share repurchases, strong EPS growth, and successful product launches. However, concerns arise from the reduced revenue guidance, increased expenses, and unclear future growth plans. The Q&A session highlighted uncertainties in management's responses and potential risks from tariff impacts. These mixed factors balance each other out, leading to a neutral sentiment prediction for stock price movement.
Key Financial Performance
Revenue (Vascular) $472.7 million, increased 2.4% year-over-year. Growth driven by central access, hemostatic, and atomization products, offset by prior year military surge orders that did not repeat in 2025.
Revenue (Interventional) $427.5 million, increased 8.1% year-over-year. Strong performance driven by a broad Interventional portfolio.
Revenue (Surgical) $219.3 million, increased 3.2% year-over-year. Growth impacted by volume-based procurement in China, with strong double-digit growth in core surgical franchises.
Adjusted Gross Margin 63.7%, decreased 200 basis points year-over-year. Decline due to tariffs, lower-margin Vascular Intervention acquisition, increased logistics/distribution costs, and foreign exchange.
Adjusted Operating Margin 22.7%, decreased 230 basis points year-over-year. Decline due to gross margin pressure, higher operating expenses from Vascular Intervention acquisition, and foreign exchange impact.
Adjusted Net Interest Expense $93.6 million, increased from $77.4 million in prior year. Increase due to borrowings for Vascular Intervention acquisition.
Adjusted Tax Rate 12.6%, decreased from 13.4% in prior year. Decrease due to beneficial tax provisions in the One, Big, Beautiful Bill Act, including U.S.-based R&D expense deductions.
Adjusted Earnings Per Share (EPS) $6.98, increased 8.7% year-over-year. Increase driven by higher revenue, lower tax rate, and share count, partially offset by higher interest expense and foreign exchange impact.
Cash, Cash Equivalents, and Restricted Cash $402.7 million at year-end 2025, increased from $285.3 million at year-end 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Vascular Intervention acquisition: Acquired BIOTRONIK's Vascular Intervention business, contributing to revenue growth.
R&D investment: Increased R&D investment to approximately 8% of sales, up from 5% historically, to focus on product innovation.
Strategic divestitures: Signed agreements to sell Acute Care, Interventional Urology, and OEM businesses for $2.03 billion, with net after-tax proceeds of $1.8 billion. This will streamline the portfolio and focus on priority markets.
Revenue growth: Pro forma adjusted constant currency revenue growth guidance for 2026 is 4.5% to 5.5%, reflecting a mid-single-digit growth profile.
Stranded costs: Approximately $90 million in stranded costs due to divestitures, with plans to offset these through transition and manufacturing service agreements.
Restructuring plan: Announced a restructuring plan targeting $50 million in annual pre-tax savings through workforce reductions and operational efficiencies.
Portfolio optimization: Streamlined portfolio to focus on Vascular, Interventional, and Surgical businesses, positioning Teleflex as a medical technologies leader.
Capital allocation: Plan to use $1 billion for share repurchases and remaining proceeds to reduce debt, enhancing financial flexibility and shareholder returns.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Stranded Costs: The company will incur approximately $90 million of stranded costs in 2026 due to the classification of discontinued operations. These costs are necessary to support both continuing and discontinued operations during the transition period, creating a financial burden until offset by transition service and manufacturing service agreements.
Timing of Strategic Divestitures: The exact timing of the closings of the strategic divestitures in the second half of 2026 will impact the company's ability to deploy capital and execute on its $1 billion share repurchase program and debt repayment plans, potentially delaying financial benefits.
Gross Margin Pressure: The adjusted gross margin decreased by 200 basis points in 2025 due to adverse impacts of tariffs, increased logistics and distribution costs, and the addition of the Vascular Intervention acquisition, which has a lower gross margin than the corporate average.
Operating Margin Decline: The adjusted operating margin decreased by 230 basis points in 2025 due to gross margin pressures, higher operating expenses from the Vascular Intervention acquisition, and negative foreign exchange impacts.
Interest Expense: Adjusted net interest expense increased to $93.6 million in 2025, primarily due to borrowings for the Vascular Intervention acquisition, adding financial strain.
Foreign Exchange Impact: Foreign exchange negatively impacted gross and operating margins in 2025, contributing to financial pressures.
Restructuring Costs: The company announced a restructuring plan to mitigate $50 million in stranded costs, which involves workforce reductions and capital asset rationalization. These actions are expected to be completed by mid-2028, creating short-term operational disruptions.
Tariffs: Adverse impacts of tariffs contributed to a 200 basis point decrease in gross margin in 2025, adding to cost pressures.
Volume-Based Procurement in China: The surgical business faced challenges due to volume-based procurement in China, which impacted revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Adjusted EPS Guidance: The adjusted EPS guidance for 2026 is projected to be in the range of $6.25 to $6.55. This includes assumptions such as $90 million in stranded costs related to strategic divestitures, which are expected to be offset by transition services and manufacturing services agreements upon closing of the divestitures. The guidance does not include the positive impact of a $1 billion share repurchase program or debt repayment, which are expected to significantly enhance EPS in 2027 and beyond.
2026 Revenue Growth Guidance: Pro forma adjusted constant currency revenue growth for 2026 is expected to be in the range of 4.5% to 5.5%. This growth is based on the continuing operations of the company and excludes the divested Acute Care, Interventional Urology, and OEM businesses.
Strategic Divestitures and Financial Impact: The company expects to close the divestitures of Acute Care, Interventional Urology, and OEM businesses in the second half of 2026, generating approximately $1.8 billion in after-tax proceeds. These proceeds will be used for a $1 billion share repurchase program and debt reduction. Transition services and manufacturing services agreements are expected to fully offset $90 million in stranded costs on an annualized basis post-divestiture.
2026 Adjusted Operating Margin: The adjusted operating margin for 2026 is expected to be approximately 19%, reflecting the full impact of $90 million in stranded costs. Once the divestitures close, the operating margin is expected to improve to a steady-state profile of approximately 23%.
2027 and Beyond Financial Outlook: The company anticipates significant improvements in adjusted EPS in 2027 and beyond, driven by the benefits of strategic divestitures, cost-saving initiatives, and capital deployment actions such as share repurchases and debt reduction.
R&D Investment: R&D expenses for the continuing operations (RemainCo) are expected to represent approximately 8% of sales in 2026, compared to 5% historically, reflecting a strategic focus on product innovation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Authorization: Teleflex has announced a share repurchase authorization of up to $1 billion. This is part of their strategy to return significant capital to shareholders using the net proceeds from the divestitures of their Acute Care, Interventional Urology, and OEM businesses.
Capital Deployment: The company plans to execute the share repurchase program following the closing of the strategic divestitures, which are expected in the second half of 2026. This is intended to reduce the share count and enhance shareholder value.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the mix of the $1.8 billion proceeds from divestitures between share repurchases and debt repayment?
A:$1 billion will be used for share repurchases, and $800 million will be allocated to debt repayment. Specifically, $700 million will go towards the deferred draw revolver for the Bison acquisition, and $100 million will be applied to the revolver.
Q:Are the restructuring savings of $48 million to $52 million baked into the EPS guidance range of $6.25 to $6.55?
A:Yes, the current restructuring savings for 2026 are included in the guidance. Additionally, there is a line of sight for $50 million in savings post-2026 from two restructurings.
Q:What is the pro forma growth rate for the second half, and is there a first half or full-year number?
A:The pro forma growth rate for the second half is 4.7%, which is considered the most representative growth profile. No specific first half or full-year organic growth numbers were provided.
Q:What is driving double-digit growth in the Surgical segment, and how much VBP impact remains for 2026?
A:Double-digit growth is driven by strength across the portfolio, particularly the refreshed instrument line aimed at ear, nose, and throat procedures, and ligation. The VBP impact is mostly behind, with some remaining in 2026.
Q:Are there any stranded costs in the pro forma cost profile?
A:Yes, there are $90 million of stranded costs in the P&L, which are being managed through TSA and MSA arrangements and restructuring programs to fully mitigate them.
Q:Is tuck-in M&A still a driver for medium-term growth?
A:Tuck-in M&A may be considered if opportunities arise, but no significant M&A is expected in 2026 as the focus is on integrating the BIOTRONIK acquisition and completing the separation and sale.
Q:What are the strategic priorities and growth expectations for 2027 and beyond?
A:No specific long-range plan or growth profiles for 2027 were provided. However, mid-single-digit growth, stranded cost mitigation, debt paydown, and share buybacks are expected to result in margin improvement and EPS uplift.
Q:What qualities are being sought in the CEO search?
A:The company is looking for a leader with experience in midsized, high-growth organizations operating globally, particularly in high-acuity hospital settings.
Q:How are recent tariff rulings affecting the outlook for Canadian operations?
A:The plan includes expected tariffs, with $18 million additional tariffs in 2023, totaling $35 million. There is uncertainty about future tariffs and potential refunds, and any savings from tariff changes would take at least two quarters to materialize.
Q:What is the update on BIOTRONIK integration?
A:The integration is progressing well, with sales force integration completed and no significant talent losses. Revenue synergies are expected, and the sales forces are fully integrated and working together.
Q:What is the R&D investment focus for RemainCo?
A:R&D investment has increased to 8% of revenue, primarily due to BIOTRONIK and additional investments in the interventional and vascular spaces. Surgical R&D investment has increased to a lesser extent.
Q:Can margins continue to expand after TSAs go away?
A:Yes, margins are expected to expand through cost-saving initiatives, P&L leverage from growth, and maintaining a lean OpEx base.
Q:What gives confidence in the 2026 revenue growth guidance?
A:Confidence comes from sales synergies from the BIOTRONIK integration, easier comps due to reduced VBP impacts, and a step-up in growth throughout the year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific growth profiles or long-range plans for 2027 and beyond, instead suggesting that analysts model mid-single-digit growth and leverage opportunities. They also did not confirm specific EPS figures for 2026 or 2027, leaving analysts to make their own calculations. Additionally, there was uncertainty and lack of clarity regarding the impact of recent tariff rulings and potential refunds.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Acute Care
CEO
Care Interventional
Interventional Urology
OEM business
Stuart
Urology OEM
Vascular Intervention
acquisition
action
closing divestiture
context
creation
end
exchange
factor
forma currency
increase
interest expense
manufacturing service
margin
priority
proceeds divestiture
restructuring
service agreement
service arrangement
service manufacturing
share repurchase
tax
transition service
TFX Transcript
Teleflex Incorporated (TFX) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents mixed signals: a positive shareholder return plan with significant share repurchases, strong EPS growth, and successful product launches. However, concerns arise from the reduced revenue guidance, increased expenses, and unclear future growth plans. The Q&A session highlighted uncertainties in management's responses and potential risks from tariff impacts. These mixed factors balance each other out, leading to a neutral sentiment prediction for stock price movement.
Teleflex Incorporated (TFX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-18
Teleflex Incorporated (TFX) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights several positive factors: increased revenue growth guidance, improved adjusted gross margins, and strong performance in the Vascular Intervention business. The Q&A session further supports this with positive insights on market share growth and successful integration of acquisitions. Although cash flow from operations decreased, the overall financial outlook and strategic plans, including a focus on maximizing shareholder value through a potential sale, suggest a positive sentiment. The upward revision of guidance and strong market performance indicate a likely positive stock price movement in the short term.
Teleflex Incorporated (TFX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-10
TFX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
